Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Lars Erik Kristensen; Elisabeth Lie; Lennart Jacobsson; Robin Christensen; Philip J Mease; Henning Bliddal; Pierre Geborek

doi:10.3899/jrheum.150744

Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Lars Erik Kristensen, Elisabeth Lie, Lennart Jacobsson, Robin Christensen, Philip J Mease, Henning Bliddal, Pierre Geborek

Skåne University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.

Original language	English
Pages (from-to)	81-87
Journal	Journal of Rheumatology
Volume	43
Issue number	1
DOIs	https://doi.org/10.3899/jrheum.150744
Publication status	Published - 2016
Externally published	Yes

Subject classification (UKÄ)

Rheumatology and Autoimmunity

Access to Document

10.3899/jrheum.150744

http://www.ncbi.nlm.nih.gov/pubmed/26628604?dopt=Abstract

Cite this

@article{6b9b5b962b3043399f1e3c2c34ce8fd7,

title = "Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.",

abstract = "Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.",

author = "Kristensen, {Lars Erik} and Elisabeth Lie and Lennart Jacobsson and Robin Christensen and Mease, {Philip J} and Henning Bliddal and Pierre Geborek",

year = "2016",

doi = "10.3899/jrheum.150744",

language = "English",

volume = "43",

pages = "81--87",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Company Limited",

number = "1",

}

TY - JOUR

T1 - Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

AU - Kristensen, Lars Erik

AU - Lie, Elisabeth

AU - Jacobsson, Lennart

AU - Christensen, Robin

AU - Mease, Philip J

AU - Bliddal, Henning

AU - Geborek, Pierre

PY - 2016

Y1 - 2016

N2 - Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.

AB - Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.

U2 - 10.3899/jrheum.150744

DO - 10.3899/jrheum.150744

M3 - Article

C2 - 26628604

VL - 43

SP - 81

EP - 87

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 1

ER -

Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this